-+ 0.00%
-+ 0.00%
-+ 0.00%

Cingulate Receives U.S. Patent for CTx-2103 Anxiety Treatment Formulation

PUBT·11/19/2026 14:29:27
Listen to the news
Cingulate Receives U.S. Patent for CTx-2103 Anxiety Treatment Formulation
  • Cingulate received a U.S. patent covering its buspirone tablet formulation for CTx-2103, an anxiety treatment candidate.
  • The formulation uses proprietary Precision Timed Release technology to deliver medication at three predetermined times throughout the day from one tablet.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190929PRIMZONEFULLFEED9880948) on November 19, 2026, and is solely responsible for the information contained therein.